155 related articles for article (PubMed ID: 29775621)
1. Methylation of NBPF1 as a novel marker for the detection of plasma cell-free DNA of breast cancer patients.
Li D; Li P; Wu J; Yi J; Dou Y; Guo X; Yin Y; Wang D; Ma C; Qiu L
Clin Chim Acta; 2018 Sep; 484():81-86. PubMed ID: 29775621
[TBL] [Abstract][Full Text] [Related]
2. Methylation analysis of plasma cell-free DNA for breast cancer early detection using bisulfite next-generation sequencing.
Li Z; Guo X; Tang L; Peng L; Chen M; Luo X; Wang S; Xiao Z; Deng Z; Dai L; Xia K; Wang J
Tumour Biol; 2016 Oct; 37(10):13111-13119. PubMed ID: 27449045
[TBL] [Abstract][Full Text] [Related]
3. Methylation of the SEPT9_v2 promoter as a novel marker for the detection of circulating tumor DNA in breast cancer patients.
Matsui S; Kagara N; Mishima C; Naoi Y; Shimoda M; Shimomura A; Shimazu K; Kim SJ; Noguchi S
Oncol Rep; 2016 Oct; 36(4):2225-35. PubMed ID: 27499429
[TBL] [Abstract][Full Text] [Related]
4. SOX17 promoter methylation in circulating tumor cells and matched cell-free DNA isolated from plasma of patients with breast cancer.
Chimonidou M; Strati A; Malamos N; Georgoulias V; Lianidou ES
Clin Chem; 2013 Jan; 59(1):270-9. PubMed ID: 23136251
[TBL] [Abstract][Full Text] [Related]
5. CST6 promoter methylation in circulating cell-free DNA of breast cancer patients.
Chimonidou M; Tzitzira A; Strati A; Sotiropoulou G; Sfikas C; Malamos N; Georgoulias V; Lianidou E
Clin Biochem; 2013 Feb; 46(3):235-40. PubMed ID: 23006792
[TBL] [Abstract][Full Text] [Related]
6. Circulating cell-free DNA-based epigenetic assay can detect early breast cancer.
Uehiro N; Sato F; Pu F; Tanaka S; Kawashima M; Kawaguchi K; Sugimoto M; Saji S; Toi M
Breast Cancer Res; 2016 Dec; 18(1):129. PubMed ID: 27993161
[TBL] [Abstract][Full Text] [Related]
7. Circulating cell-free DNA: a promising marker of regional lymphonode metastasis in breast cancer patients.
Agostini M; Enzo MV; Bedin C; Belardinelli V; Goldin E; Del Bianco P; Maschietto E; D'Angelo E; Izzi L; Saccani A; Zavagno G; Nitti D
Cancer Biomark; 2012; 11(2-3):89-98. PubMed ID: 23011155
[TBL] [Abstract][Full Text] [Related]
8. E74-like Factor 5 Promoter Methylation in Circulating Tumor DNA as a Potential Prognostic Marker in Breast Cancer Patients.
Salimi M; Rastegarpouyani S
Asian Pac J Cancer Prev; 2023 Dec; 24(12):4035-4041. PubMed ID: 38156835
[TBL] [Abstract][Full Text] [Related]
9. Blood-based DNA methylation as biomarker for breast cancer: a systematic review.
Tang Q; Cheng J; Cao X; Surowy H; Burwinkel B
Clin Epigenetics; 2016; 8():115. PubMed ID: 27895805
[TBL] [Abstract][Full Text] [Related]
10. Quantitative detection of methylated ESR1 and 14-3-3-sigma gene promoters in serum as candidate biomarkers for diagnosis of breast cancer and evaluation of treatment efficacy.
Martínez-Galán J; Torres B; Del Moral R; Muñoz-Gámez JA; Martín-Oliva D; Villalobos M; Núñez MI; Luna Jde D; Oliver FJ; Ruiz de Almodóvar JM
Cancer Biol Ther; 2008 Jun; 7(6):958-65. PubMed ID: 18379196
[TBL] [Abstract][Full Text] [Related]
11. Diagnostic and prognostic role of cell-free DNA testing for colorectal cancer patients.
Bedin C; Enzo MV; Del Bianco P; Pucciarelli S; Nitti D; Agostini M
Int J Cancer; 2017 Apr; 140(8):1888-1898. PubMed ID: 27943272
[TBL] [Abstract][Full Text] [Related]
12. [Detection and significance of APC gene promoter hypermethylation in serum of breast cancer patients].
Zhang JJ; Ouyang T; Wan WH; Xu GW; Deng GR
Ai Zheng; 2007 Jan; 26(1):44-7. PubMed ID: 17222366
[TBL] [Abstract][Full Text] [Related]
13. Concentration and Methylation of Cell-Free DNA from Blood Plasma as Diagnostic Markers of Renal Cancer.
Skrypkina I; Tsyba L; Onyshchenko K; Morderer D; Kashparova O; Nikolaienko O; Panasenko G; Vozianov S; Romanenko A; Rynditch A
Dis Markers; 2016; 2016():3693096. PubMed ID: 27725787
[TBL] [Abstract][Full Text] [Related]
14. Detection of aberrant methylation of a six-gene panel in serum DNA for diagnosis of breast cancer.
Shan M; Yin H; Li J; Li X; Wang D; Su Y; Niu M; Zhong Z; Wang J; Zhang X; Kang W; Pang D
Oncotarget; 2016 Apr; 7(14):18485-94. PubMed ID: 26918343
[TBL] [Abstract][Full Text] [Related]
15. Free circulating tumor DNA as a diagnostic marker for breast cancer.
Hashad D; Sorour A; Ghazal A; Talaat I
J Clin Lab Anal; 2012 Nov; 26(6):467-72. PubMed ID: 23143630
[TBL] [Abstract][Full Text] [Related]
16. Promoter methylation of TRIM9 as a marker for detection of circulating tumor DNA in breast cancer patients.
Mishima C; Kagara N; Matsui S; Tanei T; Naoi Y; Shimoda M; Shimomura A; Shimazu K; Kim SJ; Noguchi S
Springerplus; 2015; 4():635. PubMed ID: 26543769
[TBL] [Abstract][Full Text] [Related]
17. LINE-1 hypomethylation status of circulating cell-free DNA in plasma as a biomarker for colorectal cancer.
Nagai Y; Sunami E; Yamamoto Y; Hata K; Okada S; Murono K; Yasuda K; Otani K; Nishikawa T; Tanaka T; Kiyomatsu T; Kawai K; Nozawa H; Ishihara S; Hoon DS; Watanabe T
Oncotarget; 2017 Feb; 8(7):11906-11916. PubMed ID: 28060757
[TBL] [Abstract][Full Text] [Related]
18. Comprehensive DNA methylation analysis of tissue of origin of plasma cell-free DNA by methylated CpG tandem amplification and sequencing (MCTA-Seq).
Liu X; Ren J; Luo N; Guo H; Zheng Y; Li J; Tang F; Wen L; Peng J
Clin Epigenetics; 2019 Jun; 11(1):93. PubMed ID: 31234922
[TBL] [Abstract][Full Text] [Related]
19. NBPF1, a tumor suppressor candidate in neuroblastoma, exerts growth inhibitory effects by inducing a G1 cell cycle arrest.
Andries V; Vandepoele K; Staes K; Berx G; Bogaert P; Van Isterdael G; Ginneberge D; Parthoens E; Vandenbussche J; Gevaert K; van Roy F
BMC Cancer; 2015 May; 15():391. PubMed ID: 25958384
[TBL] [Abstract][Full Text] [Related]
20. Prediction of blood-based biomarkers and subsequent design of bisulfite PCR-LDR-qPCR assay for breast cancer detection.
Bacolod MD; Huang J; Giardina SF; Feinberg PB; Mirza AH; Swistel A; Soper SA; Barany F
BMC Cancer; 2020 Jan; 20(1):85. PubMed ID: 32005108
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
